INFORMATION Scientific Organizer Prof. Dr. med. Nisar P. Malek Ärztlicher Direktor Medizinische Universitätsklinik Abteilung Innere Medizin I Otfried-Müller-Str. 10 72076 Tübingen Fon: +49 (0)7071 298 272-1 Fax: +49 (0)7071 292 095 Email: [email protected] VENUE & NOTES Hotel Pullman Berlin Schweizerhof Budapester Straße 25 10787 Berlin Germany Angelika Gohde Sekretariat Prof. Malek Medizinische Universitätsklinik Tübingen Abteilung Innere Medizin I Otfried-Müller-Str. 10 72076 Tübingen Fon: +49 (0)7071 298 272-2 Fax: +49 (0)7071 292 095 Email: [email protected] Authorized Congress Agency eration In Coop with: Certification: 6 CME Points 5 AIO Points ravel rged. T a h c e b ot arate . A sep he e will n d e f e s n r io u t in t ipa imb A partic will not be re to participate s y e r s a expen necess s”. ation is ngres registr erbstko H O I A „11. e visit: n pleas io t a m r o ss.de ther inf For fur herbstkongre iowww.a n: Attentio 4 ber 201 0th Octo ocx) doc or .d (. a le tr fi s b d r A o ct as a w r abstra roup.com. u o y d n g se ciPlease [email protected] lika.fah e g n a to line: 1 ct Dead ACADEMIC DRUG DEVELOPMENT IN ONCOLOGY - TRANSLATING BASIC SCIENCE RESEARCH INTO INNOVATIVE TREATMENTS 12th NOVEMBER 2014 IN BERLIN Congress Office MCI Deutschland GmbH | München Office Angelika Fahrner Neumarkter Str. 21, 81673 München Fon: +49 (0)89 549 096-74 Fax: +49 (0)89 549 096-75 Email: [email protected] 6th AIO - SYMPOSIUM Dear colleagues, on November 12th we will be holding our 6th AIO-Symposium on „Academic Drug Development in Oncology“. As in the previous years we will showcase a number of interesting and important advances in academic drug development. This year we will address three clinically important areas. The use of modified viruses to treat cancer is a longstanding hope in the field of oncology. Throughout the recent years this innovative approach has seen a number of different developments which have been translated into clinical trials. We will introduce these new types of oncolytic therapies and describe the way forward towards individualized treatment in virus based oncologic therapies. Every cell depends on a set of core mechanisms which helps it to withstand stress, regulate its metabolism and control aging. Interestingly such mechanisms can also be exploited to device innovative new treatments which might help to overcome resistance and result in longstanding responses. We will therefore introduce new targets in metabolism, ageing and autophagy and discuss their potential use in oncology. The organisation and funding of academic drug development is an important pillar in the generation of new treatments. It involves universities, research institutes outside academia and also a close collaboration with industry. In the last part of the symposium we will present these different approaches and also try to understand how they can interact in the most productive way. PROGRAM CHAIRS & SPEAKERS 09.00 Welcome Dr. Matthias Gottwald, Bayer HealthCare, Leverkusen Session 1: Using viruses to treat cancer (Chair: Ulrich M. Lauer, Tübingen) 09.10-09.35 09.45-10.10 10.20-10.50 Coffee Break 10.50-11.15 11.25-11.35 Virotherapeutic Vectors in Current Clinical Evaluation Ulrich M. Lauer, Tübingen Short talk 1 11.45-13.00 Lunch Session 2: Targeting cellular homeostasis (Chair: Ingrid Hoffmann, Heidelberg) 13.00-13.25 14.45-15.10 DNA damage induced differentiation suppresses mutation accumulation in aging stem cells and carcinogenesis Lenhard Rudolph, Jena ATG5: a multitasking molecule Hans-Uwe Simon, Bern The Role of Glucose and Lipid Metabolism in Growth and Survival of Cancer Cells Almut Schulze, Würzburg Short talk 2 15.15-15.45 Coffee break Session 3: Academic drug development (Chair: Nisar P. Malek, Tübingen) 15.45-16.10 Natural >Synthetic >Targeted Anticancer Agents Ludger Wessjohann, Halle IMI1 and 2, new ways to optimize R&D in drug development Matthias Gottwald, Leverkusen Concluding remarks Nisar Malek, Tübingen 13.35-14.00 14.10-14.35 As in our previous years we are also inviting young investigators to submit abstracts which will be chosen for short presentations within this meeting. We hope that as in our previous symposiums we will be able to connect different areas of drug development to help bridge the gap between basic research and clinical application. I am very happy to invite you to join us in Berlin for this transdisciplinary symposium. With best regards Prof. Dr. Nisar P. Malek for the AIO-Arbeitsgruppe Wirkstoffentwicklung frühe Phase I/II-Studien Principles of Tumor Targeted Virotherapeutics Michael Mühlebach, Langen Engineering Measles Virus for Cancer Therapy Guy Ungerechts, Heidelberg 16.20-16.55 17.05 Prof. Dr. med. Volker Heinemann Klinikum der Universität München - Großhadern, München Prof. Dr. Ingrid Hoffmann Deutsches Krebsforschungszentrum, Heidelberg Prof. Dr. med. Ulrich M. Lauer Universitätsklinikum Tübingen, Tübingen Prof. Dr. med. Nisar P. Malek Universitätsklinikum Tübingen, Tübingen Dr. Michael Mühlebach Paul-Ehrlich-Institut, Langen Prof. Dr. K. Lenhard Rudolph Leibniz-Institut für Altersforschung - Fritz-Lipmann-Institut e.V. (FLI), Jena Prof. Dr. Almut Schulze Julius-Maximilians-Universität Würzburg, Würzburg Prof. Dr. Dr. Hans-Uwe Simon University of Bern, Bern PD Dr. med. Dr. rer. nat. Guy Ungerechts Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg Prof. Dr. Ludger Wessjohann Leibniz-Institut für Pflanzenbiochemie, Halle (Saale) The lectures and discussions will be held in English language.
© Copyright 2018